ArticleOncology letters2026
Pretreatment C-reactive protein-triglyceride-glucose index predicts survival in patients with FLOT-treated locally advanced gastric and gastroesophageal junction cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The C-reactive protein-triglyceride-glucose index (CTI), integrating C-reactive protein and the triglyceride-glucose index, is a pragmatic biomarker reflecting systemic inflammation and metabolic stress in cancer. Although its prognostic value has been validated in heterogeneous cancer cohorts, data in homogeneous perioperative settings remain limited. The present study retrospectively evaluated 131 patients with locally advanced gastric or gastroesophageal junction adenocarcinoma who received perioperative fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy between November 2018 and June 2024 (67 months). CTI was calculated at diagnosis, and patients were stratified using the 4.78 cut-off value previously validated in oncology populations. Associations between CTI and clinicopathological variables, pathological response, progression-free survival (PFS) and overall survival (OS) were analyzed. The results demonstrated that among the 131 patients who underwent curative-intent surgery after neoadjuvant FLOT, 113 (86.3%) had low CTI (<4.78) and 18 (13.7%) had high CTI (≥4.78). Patients with high CTI had significantly shorter PFS compared with those with low CTI (median, 12.2 vs. 25.5 months; P=0.006). OS was also markedly inferior in the high CTI group [median, 23.1 months vs. not reached (NR) in the low CTI group; P=0.001]. In the multivariable analysis, high CTI independently predicted poor PFS [hazard ratio (HR), 2.18; 95% confidence interval (CI), 1.21-3.95; P=0.010]. Regarding treatment response, the pathological complete response rate was 11.5% (13/113) in the low CTI group and 22.2% (4/18) in the high CTI group (P=0.221), indicating no significant association between CTI and pathological complete response. In conclusion, pretreatment CTI is an independent prognostic marker in patients with locally advanced gastric or gastroesophageal junction adenocarcinoma treated with perioperative FLOT, identifying individuals at higher risk of relapse and inferior survival. The simplicity, low cost and pretherapeutic availability of pretreatment CTI support its use as a promising tool for risk stratification that warrants prospective, multicenter validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.